Trial Profile

The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Apr 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tumour necrosis factor alpha inhibitors
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms DREAM-TIME

Most Recent Events

30 Oct 2013 Preliminary results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
16 Feb 2012 Additional lead trial centre identified as reported by Netherlands Trial Register.
16 Feb 2012 Planned End Date changed from 31 Dec 2011 to 31 Mar 2013 as reported by Netherlands Trial Register.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com